Luigi F.
- Country
- Italy
- Department
- DIMES
Research Overview
- Randomized trial of RD03/2016 (levofloxacin/ketorolac) versus dexamethasone/levofloxacin eye drops for inflammation/infection after cataract surgery
- Evaluation of Isocyclosporin A Eye Drop Solution Efficacy and Safety in Adult Atopic Keratoconjunctivitis: A Randomized, Double-Masked, Vehicle-Controlled Study
- A phase III multicenter, double-blind, randomized, placebo-controlled, parallel-group trial of the efficacy of citicoline eyedrops 2% on visual field preservation in patients with open angle glaucoma
Data & Insights
Has run more than one trial at 14 of 59 partner sites.
Specializations
Ophthalmic Disorders
The investigator specializes in various eye conditions, with particular emphasis on Atopic Keratoconjunctivitis (AKC) and glaucoma management. Their research encompasses innovative therapeutic approaches for chronic ocular conditions.
- Inflammatory Eye Disorders
- Glaucoma Treatment
- Ocular Surface Disease
Through clinical investigation of novel eye drop formulations and therapeutic compounds for ocular conditions.
Therapeutic Focus
The investigator concentrates on evaluating treatments for vision preservation and symptom management in ocular diseases, including neuroprotective approaches and anti-inflammatory therapies.
- Visual Field Preservation
- Ocular Immunology
- Progressive Eye Disease Management
Expertise in assessing novel therapeutic agents for chronic ophthalmic conditions.
Clinical Interests
Focused on developing treatment strategies for open angle glaucoma and inflammatory eye conditions, with particular attention to patient comfort and therapeutic efficacy.
- Ocular Drug Delivery
- Vision Protection
- Symptom Control
Dedicated to advancing therapeutic options for patients with chronic eye conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.